MX2021004169A - Composiciones y metodos para la transfeccion de celulas. - Google Patents

Composiciones y metodos para la transfeccion de celulas.

Info

Publication number
MX2021004169A
MX2021004169A MX2021004169A MX2021004169A MX2021004169A MX 2021004169 A MX2021004169 A MX 2021004169A MX 2021004169 A MX2021004169 A MX 2021004169A MX 2021004169 A MX2021004169 A MX 2021004169A MX 2021004169 A MX2021004169 A MX 2021004169A
Authority
MX
Mexico
Prior art keywords
compositions
methods
transfecting cells
polyplexes
safe
Prior art date
Application number
MX2021004169A
Other languages
English (en)
Inventor
Lara Cutlar
Wenxin Wang
Original Assignee
Amryt Genetics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amryt Genetics Ltd filed Critical Amryt Genetics Ltd
Publication of MX2021004169A publication Critical patent/MX2021004169A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G73/00—Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
    • C08G73/02—Polyamines
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G73/00—Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
    • C08G73/02—Polyamines
    • C08G73/024—Polyamines containing oxygen in the form of ether bonds in the main chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/641—Branched, dendritic or hypercomb peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G83/00—Macromolecular compounds not provided for in groups C08G2/00 - C08G81/00
    • C08G83/002—Dendritic macromolecules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Abstract

La presente descripción se refiere a poliplejos y polímeros ramificados que son útiles para aplicaciones de terapia génica como agentes de transfección de ácidos nucleicos seguros y no tóxicos.
MX2021004169A 2018-10-12 2019-10-14 Composiciones y metodos para la transfeccion de celulas. MX2021004169A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862744994P 2018-10-12 2018-10-12
US201962826461P 2019-03-29 2019-03-29
PCT/US2019/056151 WO2020077347A2 (en) 2018-10-12 2019-10-14 Compositions and methods for transfecting cells

Publications (1)

Publication Number Publication Date
MX2021004169A true MX2021004169A (es) 2021-08-05

Family

ID=68387441

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021004169A MX2021004169A (es) 2018-10-12 2019-10-14 Composiciones y metodos para la transfeccion de celulas.

Country Status (13)

Country Link
US (1) US20220040331A1 (es)
EP (1) EP3864070A2 (es)
JP (1) JP2022514113A (es)
KR (1) KR20210072773A (es)
CN (1) CN113260657A (es)
AU (1) AU2019356596A1 (es)
BR (1) BR112021006861A2 (es)
CA (1) CA3114205A1 (es)
CO (1) CO2021004463A2 (es)
IL (1) IL282160A (es)
MX (1) MX2021004169A (es)
SG (1) SG11202102538RA (es)
WO (1) WO2020077347A2 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3700965A1 (en) 2017-10-27 2020-09-02 Massachusetts Institute of Technology Poly (beta-amino esters) and uses thereof
CN108753813B (zh) * 2018-06-08 2021-08-24 中国水稻研究所 获得无标记转基因植物的方法
EP4305088A1 (en) * 2021-03-09 2024-01-17 Massachusetts Institute of Technology Branched poly(-amino esters) for the delivery of nucleic acids

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9109012B2 (en) 2007-05-29 2015-08-18 Nature Technology Corporation Vectors and method for genetic immunization
GB201413907D0 (en) 2014-08-06 2014-09-17 Nat Univ Ireland Hyberbranched poly(beta-amino ester) for gene therapy

Also Published As

Publication number Publication date
CO2021004463A2 (es) 2021-04-30
WO2020077347A3 (en) 2020-05-22
SG11202102538RA (en) 2021-04-29
BR112021006861A2 (pt) 2021-07-13
AU2019356596A1 (en) 2021-04-08
CA3114205A1 (en) 2020-04-16
CN113260657A (zh) 2021-08-13
US20220040331A1 (en) 2022-02-10
KR20210072773A (ko) 2021-06-17
EP3864070A2 (en) 2021-08-18
IL282160A (en) 2021-05-31
JP2022514113A (ja) 2022-02-09
WO2020077347A2 (en) 2020-04-16

Similar Documents

Publication Publication Date Title
MX2021014368A (es) Metodos y composiciones para la modificacion dirigida de un genoma.
MX2022003116A (es) Factor ix modificado, y composiciones, metodos y usos para la transferencia de genes a celulas, organos y tejidos.
AU2017335890B2 (en) RNA-guided nucleic acid modifying enzymes and methods of use thereof
MX2018001617A (es) Composiciones de crispr-cas9 diseñados y metodos de uso.
AU2024202345A1 (en) Nucleic acid carriers and therapeutic methods of use
PH12017501956A1 (en) Compositions of obeticholic acid and methods of use
WO2017044857A3 (en) Methods and compositions for the treatment of glaucoma
MX2017004039A (es) Fosforamiditas de n-acetilgalactosamina (galnac), conjugados de acido nucleico de las mismas y su uso.
EP4321623A3 (en) Methods and compositions for genome editing in non-dividing cells
GB2557123A (en) Modified cells and methods of therapy
MX2021004169A (es) Composiciones y metodos para la transfeccion de celulas.
PH12016500395A1 (en) Cell penetrating conjugates and methods of use thereof
SG10201805815YA (en) Rna-guided gene drives
MX2017004890A (es) Metodos y composiciones para la generación o el mantenimiento de células pluripotentes.
MX2017008190A (es) Metodos y composiciones para la modificacion genetica dirigida a traves de direccionamiento multiple de una sola etapa.
EP4241784A3 (en) Artificial nucleic acid molecules for improved protein expression
GB2542653A (en) Methods and compositions for treating cells for transplant
BR112017012482A2 (pt) copolímero estático, composição, uso de um copolímero, e, métodos para liberar um ácido nucleico a uma célula ou tecido alvo e para a produção do copolímero.
WO2016057951A3 (en) Crispr oligonucleotides and gene editing
IN2014MN02141A (es)
WO2018185709A9 (en) Compositions for reprogramming cells into dendritic cells or antigen presenting cells, methods and uses thereof
MY195386A (en) Aav Treatment Of Huntington's Disease
MX2020003339A (es) Arn guía de cpf1 modificado.
MX2017004927A (es) Metodos de evaluacion genomica en ganado.
AU2017254665A1 (en) Compositions and methods for enhanced gene expression of pklr